Search
Inbakicept
go.drugbank.com/drugs/DB16479InvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also
Methyl-D9-choline
go.drugbank.com/drugs/DB12628InvestigationalMethyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).
EA-2353
go.drugbank.com/drugs/DB18506InvestigationalEA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.
Renzapride
go.drugbank.com/drugs/DB04917InvestigationalIt has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.
Alfaxalone
go.drugbank.com/drugs/DB11371ExperimentalVet approvedAlong with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin. … It is used in veterinary practice under the trade name Alfaxan, and is licensed for use in both dogs and cats.
Propylene glycol
go.drugbank.com/drugs/DB01839ApprovedInvestigationalA clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Mixtures: Mycellcare iT sSelamectin
go.drugbank.com/drugs/DB11459ExperimentalVet approvedIt also removes 2 types of lungworm in cats and one type of lungworm in dogs. It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin.
N-Ethyl-5'-Carboxamido Adenosine
go.drugbank.com/drugs/DB03719ExperimentalExperimentally, it inhibits cAMP and cGMP phosphodiesterase activity. [PubChem]
ST-003
go.drugbank.com/drugs/DB18197ExperimentalST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalIt represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.